Biosimilar Benefits to Patients, Health Care Professionals and the U.S. Market

Monday June 24, 2019

Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars Council to talk about biosimilars, their benefits and the hurdles to adoption in the United States.

Dr. Awsare works closely with patients who are directly impacted by the promise of biosimilars. His knowledge of the industry and work with Kaiser Permanente – a leader driving the adoption of biosimilars – gives him a unique perspective on this important issue.

Watch and learn more about these important medicines, including:

  • What a biosimilar is.
  • The safety studies completed to demonstrate that switching between a brand biologic and biosimilar is safe.
  • How stakeholders can increase biosimilars uptake in the United States.

Dr. Sameer Awsare, Internal Medicine Physician, Associate Executive Director, Kaiser Permanente Medical Group, answers the following questions:

  1. What is a biosimilar?
  2. Are biosimilars safe?
  3. What are the hurdles to biosimilar adoption in the United States?
  4. Will increased biosimilar use benefit the United States healthcare system?

Watch the video for his answers and view the Biosimilars Council Handbook for more information.


About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.

  • This field is for validation purposes and should be left unchanged.

Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:

February 14-16, 2022 | Orlando, Florida

Access! brings together policymakers, influential speakers and industry leaders to chart the future of generics and biosimilars. This year, we're pleased to be meeting in person for the first time since 2019! Sign up before December 31, 2021 to receive $500 off your full-pass registration.

Recent Tweets

Proposals included in #BuildBackBetter undermine the progress and promise of future #biosimilar savings, particularly for employers and patients in commercial health insurance markets.

Learn more in our latest blog post: https://biosimilarscouncil.org/resource/proposed-bbb-negotiation-framework-discourages-biosimilar-competition-imposes-higher-costs-on-commercially-insured-patients-and-their-employers/

Load More...